Featured News
Press Release
Alzheimer’s Association Welcomes Continued Progress in Alzheimer’s Treatment with FDA Approval of Leqembi Subcutaneous Starter Dose
Chicago, July 13, 2026 — The Alzheimer’s Association welcomes today’s U.S. Food and Drug Administration (FDA) action to approve a subcutaneous starter dose of Leqembi® (lecane...
All News
Press Release
Alzheimer’s Association Welcomes Continued Progress in Alzheimer’s Treatment with FDA Approval of Leqembi Subcutaneous Starter Dose
Chicago, July 13, 2026 — The Alzheimer’s Association welcomes today’s U.S. Food and Drug Administration (FDA) action to approve a...
Press Release
Alzheimer’s Association and Alzheimer’s Impact Movement Statement on OMB’s Proposed Rule on Federal Financial Assistance
Chicago, July 13, 2026 — The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM) are concerned about a proposed rule...
AIM Blog
Recognizing AIM’s July Advocate of the Month: Dalma Riquelme
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
AIM Blog
Thirteen for Thirteen
A common question I hear about the ASAP Act is some version of: can this actually pass? In this week’s...
AIM Blog
The Window We Keep Missing
When I talk about the ASAP Act, the word I keep coming back to is “early.” It’s the whole point...
AIM Blog
Your Story Is Your Superpower
When my fellow advocates and I walked into Sen. Chris Van Hollen’s office last week for the AIM Advocacy Forum...